Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMYLTI)

Drug Name
Thyrotropin Alfa Drug Info
Therapeutic ClassDiagnostic Agents
Cross-matching ID
PubChem CID
32281
TTD Drug ID
D0H4TQ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Other types of O-glycan biosynthesis 1.83 4.77e-2 29/47 (61.7%) GALNT7;GALNT2;GALNT14;...
Steroid biosynthesis 1.78 4.55e-2 19/20 (95%) DHCR24;TM7SF2;CYP24A1;...
Galactose metabolism 1.78 3.81e-2 26/31 (83.87%) PFKL;PFKP;AKR1B1;...
Sulfur relay system -1.62 4.56e-2 5/8 (62.5%) NFS1;MPST;TST;...
Retrograde endocannabinoid signaling -1.62 4.75e-2 118/148 (79.73%) NDUFB6;NDUFAB1;NDUFB5;...
Mineral absorption -1.69 2.19e-2 48/60 (80%) SLC5A1;TRPM6;STEAP1;...
Pancreatic secretion -1.69 2.28e-2 87/102 (85.29%) PNLIPRP1;PLCB1;KCNMA1;...
Renin secretion -1.69 2.23e-2 61/69 (88.41%) PLCB1;KCNMA1;PDE1A;...
Alzheimer disease -1.70 2.23e-2 279/369 (75.61%) SLC25A6;PSMB4;NDUFB7;...
Renin-angiotensin system -1.70 2.29e-2 20/23 (86.96%) ENPEP;CPA3;AGTR1;...
Ether lipid metabolism -1.72 1.92e-2 32/49 (65.31%) AGPS;PLA2G10;PLPP3;...
Pyruvate metabolism -1.73 1.71e-2 41/47 (87.23%) ACAT1;ADH6;DLD;...
Fatty acid degradation -1.77 1.40e-2 40/43 (93.02%) HADHA;ACAT1;ADH6;...
Linoleic acid metabolism -1.79 1.19e-2 21/29 (72.41%) PLA2G1B;PLA2G2D;PLA2G6;...
Proteasome -1.84 7.98e-3 44/46 (95.65%) PSMB3;PSMB10;PSMB1;...
Retinol metabolism -1.84 8.59e-3 41/68 (60.29%) CYP3A5;CYP2C18;PNPLA4;...
Thermogenesis -1.85 9.31e-3 173/232 (74.57%) COX15;RPS6KA6;CREB3L1;...
Metabolism of xenobiotics by cytochrome P450 -1.89 5.08e-3 49/77 (63.64%) UGT2B28;UGT2B17;UGT2A3;...
Nitrogen metabolism -1.90 2.23e-3 16/17 (94.12%) GLUD2;GLUD1;CA4;...
Pathways of neurodegeneration -1.95 0.00e+0 354/475 (74.53%) NDUFB6;SQSTM1;NDUFAB1;...
Diabetic cardiomyopathy -1.95 0.00e+0 162/203 (79.8%) NDUFB6;NDUFAB1;NDUFB5;...
Prion disease -1.96 0.00e+0 209/273 (76.56%) NDUFB6;NDUFAB1;NDUFB5;...
Huntington disease -1.97 0.00e+0 233/306 (76.14%) NDUFB6;NDUFAB1;NDUFB5;...
Ribosome -1.98 0.00e+0 113/158 (71.52%) MRPL33;RPS14;RPL29;...
Drug metabolism -2.00 0.00e+0 78/151 (51.66%) GUSB;UGT2B28;UGT2B17;...
Amyotrophic lateral sclerosis -2.04 0.00e+0 267/364 (73.35%) NDUFB6;CASP1;SQSTM1;...
Oxidative phosphorylation -2.30 0.00e+0 93/133 (69.92%) ATP5MC1;NDUFS1;NDUFB6;...
Parkinson disease -2.49 0.00e+0 176/249 (70.68%) ATP5MC1;ATF6;NDUFS1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H